Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Yuviwel Prior Auth Policy | Ope…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Yuviwel Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity-limit approval for Yuviwel (navepegritide) for Boeing commercial members, including initial and renewal criteria, quantity-limit exceptions, required documentation, and a 12-month approval duration.

    Policy Summary
    PayerPrime Therapeutics
    PolicyYuviwel Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Yuviwel with documentation supporting the applicable indication, clinical criteria, and quantity requested.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval duration
    3Covered strengths
    4 vials1.3 mg and 2.8 mg limit
    8 vials5.5 mg limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Boeing
    Client formulary

    Coverage Criteria

    Initial Therapy

    Covered for initial therapy when ONE of the following indication pathways is met, AND all additional requirements are satisfied.

    Achondroplasia pathway

    • ONE of

      • The patient has a diagnosis of achondroplasia confirmed by genetic testing (e.g., FGFR3).

        Medical records required.

      • The patient has radiographic findings with signs and symptoms consistent with achondroplasia, such as short stature with marked shortening of the extremities due to rhizomelia, characteristic facial configuration, or trident hand.

        Medical records required.

    • The patient has open epiphyses.

      Chart notes required.

    "{"operator":"all","label":"Other FDA-labeled indication pathway","children":[{"text":"The patient has another FDA-labeled indication for the requested agent and route of administration."},{"operator":"any","label":"ONE of","children":[{"text":"The patient's age is within FDA labeling for the requested indication for the requested agent."},{"text":"There is support for using the requested agent for the patient's age for the requested indication."}]}]}

    Additional requirements

    • The patient's baseline annualized growth velocity has been measured prior to treatment with the requested agent.
    • The patient has not had limb-lengthening surgery and does not plan to have limb-lengthening surgery while on the requested agent.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient will not use the requested agent in combination with Voxzogo or a growth hormone agent.
    • The patient does not have any FDA-labeled contraindications to the requested agent.

    Continuation or Renewal Therapy

    Continuation or renewal therapy is covered when ALL of the following conditions are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's prior authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • ONE of

      • The patient has a diagnosis of achondroplasia and has had clinical benefit with the requested agent, demonstrated by an increase in annualized growth velocity from baseline measured prior to treatment with the requested agent.
      • The patient has a diagnosis other than achondroplasia and has had clinical benefit with the requested agent.
    • If the patient has an FDA-labeled indication, ONE of

    Quantity-Limit Exception

    The requested quantity is covered when ONE of the following is met:

    ONE of

    • The requested quantity (dose) does not exceed the program quantity limit.
    • The requested quantity exceeds the program quantity limit and ONE of the following applies

      • ALL of the following

        • The requested agent does not have a maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.
      • ALL of the following

    Coverage is subject to the following restrictions: the requested agent must not be used in combination with Voxzogo or a growth hormone agent; the patient must not have had limb-lengthening surgery or plan to undergo limb-lengthening surgery while receiving the requested agent; and the patient must not have any FDA-labeled contraindications to the requested agent. FDA-labeled indication, age, route-of-administration, and other FDA-labeled exclusion requirements apply when relevant.

    Yuviwel Initial Therapy

    Yuviwel Initial Therapy

    Initial approval for Yuviwel requires ONE of the following pathways.

    Initial approval pathways

    • Achondroplasia pathway

      • Achondroplasia confirmation

        • Achondroplasia is confirmed by genetic testing, such as FGFR3 testing.
        • Achondroplasia is confirmed by radiographic findings with associated signs and symptoms, such as short stature with marked shortening of the extremities due to rhizomelia, characteristic facial configuration, or trident hand.
      • The patient has open epiphyses.

        Chart notes are required.

    Yuviwel Renewal

    Yuviwel Renewal

    Renewal approval for Yuviwel requires ALL of the following.

    Yuviwel renewal criteria

    • The patient was previously approved for Yuviwel through the plan's prior authorization process.

      Patients without prior approval require initial evaluation.

    • Clinical benefit

      • The patient has achondroplasia and has had clinical benefit with Yuviwel, indicated by an increase in annualized growth velocity from baseline measured before treatment.
      • The patient has a diagnosis other than achondroplasia and has had clinical benefit with Yuviwel.
    • FDA-labeled age criterion when applicable

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for initial and renewal requests for Yuviwel. Submit the requested indication, applicable clinical records, and supporting documentation through the plan's Prior Authorization process; approvals are generally issued for 12 months.

    • Initial requests require documentation supporting the applicable approval pathway and all clinical criteria.
    • Renewal requests require documentation of prior plan approval and continued eligibility.
    • If a quantity limit applies, submit the request under the separate Quantity Limit Criteria.
    Documentation Required

    Diagnosis, Skeletal Maturity, and Baseline Growth Documentation

    For achondroplasia, document the diagnosis and open epiphyses. The diagnosis must be confirmed in the medical record by genetic testing (for example, FGFR3) or by radiographic findings with compatible signs and symptoms.

    Yuviwel Quantity Limits

    Quantity limit
    MedicationYuviwel (navepegritide) for subcutaneous injection
    Strength1.3 mg
    Quantity limit4 vials per 28-day supply
    Quantity limit
    MedicationYuviwel (navepegritide) for subcutaneous injection
    Strength2.8 mg
    Quantity limit4 vials per 28-day supply

    Policy Background

    This policy addresses prior authorization for Yuviwel (navepegritide), primarily for patients with achondroplasia and, when applicable, other FDA-labeled indications and routes of administration. Achondroplasia must be supported by genetic testing, such as FGFR3 testing, or by characteristic radiographic findings with associated signs and symptoms; patients must have open epiphyses when required by the criteria.

    Clinical review considers skeletal maturity, the patient's baseline annualized growth velocity measured before treatment, and response during therapy. For achondroplasia, renewal requires clinical benefit demonstrated by an increase in annualized growth velocity from baseline. Other FDA-labeled indications require the applicable age eligibility or support for use at the patient's age, baseline growth documentation, specialist involvement, and compliance with the policy's surgical, combination-therapy, and contraindication requirements.

    Clinical Definitions

    Achondroplasia confirmation
    Genetic evidenceAchondroplasia may be confirmed by genetic testing, such as FGFR3 testing.
    Radiographic evidenceAchondroplasia may be confirmed by radiographic findings with associated signs and symptoms.
    Associated findingsExamples include short stature with marked shortening of the extremities due to rhizomelia, characteristic facial configuration, or trident hand.
    Baseline annualized growth velocity
    DefinitionThe patient's annualized growth velocity measured before treatment with the requested agent.
    TimingMeasurement must occur prior to treatment with the requested agent.
    Policy Summary
    PayerPrime Therapeutics
    PolicyYuviwel Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Yuviwel with documentation supporting the applicable indication, clinical criteria, and quantity requested.
    SourceLink
    On This Page
    Coverage CriteriaYuviwel Initial TherapyYuviwel RenewalAuthorization and Documentation RequirementsYuviwel Quantity LimitsPolicy BackgroundClinical Definitions
    The patient's age is within FDA labeling for the requested indication for the requested agent.
  1. There is support for using the requested agent for the patient's age for the requested indication.
  2. The patient has open epiphyses.

    Chart notes required.

  3. The patient has not had limb-lengthening surgery and does not plan to have limb-lengthening surgery while on the requested agent.
  4. The prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
  5. The patient will not use the requested agent in combination with Voxzogo or a growth hormone agent.
  6. The patient does not have any FDA-labeled contraindications to the requested agent.
  7. The requested quantity (dose) does not exceed the maximum FDA-labeled dose for the requested indication.
  8. There is support for why the requested quantity cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
  9. ALL of the following

    • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
    • There is support for therapy with a higher dose for the requested indication.
  10. Other FDA-labeled indication pathway

    • The patient has another FDA-labeled indication for Yuviwel and its route of administration.
    • Age criterion

      • The patient's age is within FDA labeling for the requested indication.
      • There is support for using Yuviwel at the patient's age for the requested indication.
    • The patient's baseline annualized growth velocity was measured before treatment with Yuviwel.
    • The patient has not had limb-lengthening surgery and does not plan to have limb-lengthening surgery while receiving Yuviwel.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or has consulted with a specialist in that area.
    • Yuviwel will not be used in combination with Voxzogo or a growth hormone agent.
    • The patient does not have an FDA-labeled contraindication to Yuviwel.
  11. The patient's age is within FDA labeling for the requested indication.
  12. There is support for using Yuviwel at the patient's age for the requested indication.
  13. The patient has open epiphyses.

    Chart notes are required.

  14. The patient has not had limb-lengthening surgery and does not plan to have limb-lengthening surgery while receiving Yuviwel.
  15. The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or has consulted with a specialist in that area.
  16. Yuviwel will not be used in combination with Voxzogo or a growth hormone agent.
  17. The patient does not have an FDA-labeled contraindication to Yuviwel.
    • Provide medical records supporting achondroplasia, including genetic testing or radiographic findings such as short stature with marked rhizomelic limb shortening, characteristic facial configuration, or trident hand.
    • Provide chart notes confirming open epiphyses.
    • Document baseline annualized growth velocity measured before treatment with the requested agent.
    Documentation Required

    Clinical Eligibility Documentation

    Document the requested indication and route of administration, along with evidence that the patient meets the applicable age and clinical eligibility requirements.

    • For an FDA-labeled indication, document that the patient's age is within FDA labeling or provide support for use at the patient's age for the requested indication.
    • Document that the patient has not had limb-lengthening surgery and does not plan to undergo limb-lengthening surgery while receiving the requested agent.
    • Identify a prescriber who is a specialist in the area of the diagnosis, such as an endocrinologist, or document specialist consultation.
    • Document that the requested agent will not be used with Voxzogo or a growth hormone agent.
    • Document absence of FDA-labeled contraindications to the requested agent.
    Documentation Required

    Renewal Response Documentation

    For renewal, document that the patient was previously approved for the requested agent through the plan's Prior Authorization process and that treatment has continued with documented clinical benefit. Patients without prior plan approval require initial evaluation review.

    • For achondroplasia, document clinical benefit as an increase in annualized growth velocity from the pretreatment baseline.
    • For an indication other than achondroplasia, document clinical benefit with the requested agent.
    • Reconfirm, as applicable, the FDA-labeled age requirement or support for use at the patient's age, open epiphyses, limb-surgery status, specialist involvement, absence of combination use with Voxzogo or a growth hormone agent, and absence of FDA-labeled contraindications.
    • Renewal approval is generally for 12 months; if a quantity limit applies, also address the Quantity Limit Criteria.

    Unsupported block type: documentation

    Denial Risk

    Clinical Criteria Not Met

    Requests may be denied when the clinical criteria are not met or required evidence is absent. This includes failure to establish the diagnosis or indication, skeletal maturity, clinical eligibility, or safe and appropriate use.

    • Diagnosis is not adequately confirmed, the requested indication or route is unsupported, or baseline annualized growth velocity is not documented.
    • Epiphyses are closed or open epiphyses are not documented when required.
    • The patient is outside the applicable FDA-labeled age range without supporting evidence for use at that age.
    • The patient has had or plans limb-lengthening surgery while receiving the agent, will use the agent with Voxzogo or a growth hormone agent, or has an FDA-labeled contraindication.
    • The patient lacks prior approval for a renewal request, or continued treatment and clinical benefit are not documented.
    • Required specialist involvement or consultation is not documented.
    Denial Risk

    Quantity-Limit Exception Unsupported

    A request for a quantity or dose above the program limit may be denied when the exception pathway is not supported by adequate clinical and dosing documentation.

    • The request does not establish that the higher dose is supported when no maximum FDA-labeled dose exists.
    • The requested quantity could be achieved with a lower quantity of a higher strength within the program limit, and no explanation is provided.
    • The requested dose exceeds the maximum FDA-labeled dose without support for therapy at the higher dose.
    Quantity limit
    MedicationYuviwel (navepegritide) for subcutaneous injection
    Strength5.5 mg
    Quantity limit8 vials per 28-day supply
    Renewal relevance
    For achondroplasia, clinical benefit is indicated by an increase in annualized growth velocity from baseline.